Innova Captab Limited (NSE:INNOVACAP)

Market Cap	49.26B -7.6%
Revenue (ttm)	16.30B +31.1%
Net Income	1.41B +9.9%
EPS	24.63 +9.9%
Shares Out	57.22M
PE Ratio	34.95
Forward PE	25.93
Dividend	4.00 (0.47%)
Ex-Dividend Date	Jan 30, 2026

Volume	33,860
Open	855.00
Previous Close	850.40
Day's Range	851.35 - 880.00
52-Week Range	622.00 - 1,020.70
Beta	-0.11
Analysts	Strong Buy
Price Target	1,078.50 (+25.29%)
Earnings Date	May 7, 2026

About Innova Captab

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinoly...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,600
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INNOVACAP

Financial Performance

In fiscal year 2026, Innova Captab's revenue was 16.30 billion, an increase of 31.06% compared to the previous year's 12.44 billion. Earnings were 1.41 billion, an increase of 9.87%.